THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.15]-CMP121 ID: TIP-MED-000391

Erythropoietin Alfa (rHuEPO) & Darbepoetin Alfa

Active Ingredient / Scientific Identity: Erythropoietin Alfa • Class: Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Complexes (Schedule H | NLEM 2022 [Iron Sucrose] | HIGH-ALERT)

⚖️ Compare Profile
Generic / Entity NameErythropoietin Alfa (rHuEPO) & Darbepoetin Alfa ([10.15]-CMP121)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassColloidal Macromolecular Carbohydrate-Shell Intravenous Iron Complexes (Schedule H | NLEM
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!).
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Erythropoietin Alfa (rHuEPO) & Darbepoetin Alfa (TIP-MED-000391, Reference Code [10.15]-CMP121) is classified under Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10) as a Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Complexes (Schedule H | NLEM 2022 [Iron Sucrose] | HIGH-ALERT). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.

4. Therapeutic Indications & Evidence-Supported Uses

  • Moderate-to-severe Iron Deficiency Anaemia (IDA) when oral iron is ineffective, not tolerated, or rapid replenishment is clinically required: 2nd and 3rd trimesters of pregnancy (Hb 5
  • 0 g/dL per MoHFW AMB guidelines), postpartum anaemia, CKD, HFrEF with iron deficiency (ferritin <100 ng/mL), IBD, and heavy uterine bleeding

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.

Administration & Meal Timing: STRICT DILUTION & OVER-DILUTION RULE: Dilute ONLY in sterile 0.9% Sodium Chloride (Normal Saline) — NEVER dilute in Dextrose (D5W) or over-dilute FCM to <2 mg Fe/mL! STOP oral iron tablets for at least 5 days after IV iron! | Single-session infusion (FCM 500–1000 mg) or Divided sessions (Iron Sucrose 200 mg q48–72h)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [10.15].
Metabolism & Biotransformation:
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
Elimination & Renal Adjustment:
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
Hepatic Impairment Considerations:
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATED in the 1ST TRIMESTER OF PREGNANCY (use only in 2nd & 3rd trimesters!), non-iron-deficiency anaemia (thalassaemia major, haemochromatosis), active bacteraemia/sepsis, and history of severe parenteral iron hypersensitivity. Resuscitation equipment (Adrenaline 1:1000 IM) MUST be at bedside and patient observed for 30 minutes post-infusion!

Key Clinical Precautions: Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, transient metallic taste, flushing, headache, mild arthralgia/myalgia 24–48h post-infusion, Fishbane reaction (transient chest/back tightness that resolves within minutes of pausing the infusion — restart at 50% slower rate after 15 min!)
  • HYPOPHOSPHATAEMIA & OSTEOMALACIA WITH FERRIC CARBOXYMALTOSE (FCM): FCM uniquely induces a sharp rise in intact FGF23, causing renal phosphate wasting and symptomatic hypophosphataemia (<2.0 mg/dL -> fatigue, muscle weakness, & osteomalacia!). Also: True anaphylaxis, and permanent dark brown skin staining (tattoo) if IV line extravasates!
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Parenteral iron blocks oral iron absorption for >=5 days — discontinue oral Ferrous Sulfate/Ascorbate before giving IV iron! ACE inhibitors increase incidence of systemic flushing/hypotensive reactions during IV iron infusion

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [10.15].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: FOUR VITAL CLINICAL & COUNTER RULES: (1) Never give IV iron in the 1st trimester of pregnancy (safe in 2nd & 3rd trimesters); (2) Never give more than 200 mg of Iron Sucrose (Orofer S) in a single day (whereas FCM [Encicarb/Orofer FCM] can be given as 500–1000 mg in a single 20-minute drip); (3) Dilute ONLY in Normal Saline (never Dextrose!); (4) Stop taking oral iron tablets when receiving an IV iron drip
    • Meal & Clock Timing Instruction: STRICT DILUTION & OVER-DILUTION RULE: Dilute ONLY in sterile 0.9% Sodium Chloride (Normal Saline) — NEVER dilute in Dextrose (D5W) or over-dilute FCM to <2 mg Fe/mL! STOP oral iron tablets for at least 5 days after IV iron! (Single-session infusion (FCM 500–1000 mg) or Divided sessions (Iron Sucrose 200 mg q48–72h))
    • Missed Dose Protocol: Single/scheduled clinic infusion
    • Geriatric Dispensing Pearl: Highly effective in older adults with HFrEF, CKD, or GI malabsorption/angiodysplasia who cannot tolerate oral iron

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ferric Carboxymaltose (FCM) Vials: 500 mg/10 mL, 1000 mg/20 mL (50 mg Fe/mL). Iron Sucrose Ampoules: 100 mg/5 mL (20 mg Fe/mL)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.